# HIV Centers for Underrepresented Populations in Research Clinical Trials Unit (CURE CTU)

> **NIH NIH UM1** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2021 · $2,047,069

## Abstract

The HIV Centers for Underrepresented Populations in Research Clinical Trials Unit (CURE CTU) will be
comprised of five highly experienced and successful Clinical Research Sites (CRS) within the continental U.S.
and a sixth new CRS located at Children’s National Medical Center in Washington, DC. Each of the CRSs has
>20 years of experience conducting clinical research in pregnant women, infants, children, adolescents and
young adults with and at-risk for HIV infection. Each of the HIV CURE CRSs is located in one of 48 counties or
in Washington DC, geographic locations that have been targeted by the U.S. President’s initiative to end the
HIV epidemic. The CURE CTU management is located at the University of California San Diego; Dr. Stephen
A. Spector will serve as the Principal Investigator. The six CRSs are located at Baylor College of
Medicine/Texas Children’s Hospital in Houston, TX, Ann & Robert H. Lurie Children’s Hospital of Chicago, IL,
Northwestern University, St. Jude Children’s Research Hospital and the University of Tennessee Health
Science Center in Memphis, TN, University of Miami, Holtz Children’s Hospital, Miami, FL, Children’s National
Medical Center in Washington, DC, and the University of California, San Diego, CA. The CURE CTU is the
only unit specifically focused on research in pregnant women, women, children, adolescents and
young adults less than 25 years in the continental U.S. funded through NIAID. The Specific Aims
address many of the targeted high priority areas of the four NIAID proposed Networks. Aim 1: Identify
novel and durable interventions to reduce reservoirs and control HIV replication in the absence of ART (ART-
free remission) (ACTG Aim 1 and IMPAACT Aim 2). Aim 2: Advance ART of pregnant and postpartum women
with HIV, to optimize maternal and infant health outcomes, and accelerate the evaluation (PK, safety, antiviral
efficacy), licensure and optimal use of potent and durable ARVs for pregnant women, infants, children and
adolescents with HIV (IMPAACT Aim 1). Aim 3: Design and conduct studies of broadly neutralizing antibodies
(bnAbs), alone and in combination, and long-acting antiretroviral agents and delivery systems for pre-exposure
prophylaxis (PrEP) (ACTG Aim 2, HPTN Aim 1, IMPAACT Aim 1). Aim 4: To investigate vaccination of HIV-
exposed and unexposed infants to induce broad immune responses including broadly neutralizing antibody
(HVTN Aim 4). Specific Aim 5: Design and conduct studies to evaluate multipurpose prevention technologies
that concurrently prevent HIV and pregnancy, sexually transmitted infections or opioid dependence (HPTN Aim
2). Aim 6: Determine optimal and feasible methods for the prevention and management of complications and
co-infections of HIV infection and their treatment in infants, children, adolescents and pregnant and postpartum
women (IMPAACT Aim 4). Aim 7: Prevent or improve the treatment of HIV-related non-infectious co-
morbidities and evaluate strategies to cure hepatitis B v...

## Key facts

- **NIH application ID:** 10056791
- **Project number:** 2UM1AI069536-15
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **Principal Investigator:** STEPHEN A SPECTOR
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,047,069
- **Award type:** 2
- **Project period:** 2007-01-01 → 2027-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10056791

## Citation

> US National Institutes of Health, RePORTER application 10056791, HIV Centers for Underrepresented Populations in Research Clinical Trials Unit (CURE CTU) (2UM1AI069536-15). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10056791. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*